• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    US Oral Mucositis Market

    ID: MRFR/Pharma/14514-HCR
    100 Pages
    Rahul Gotadki
    September 2025

    US Oral Mucositis Market Research Report By Cause (Chemotherapy, Radiotherapy, Hematopoietic Stem Cell Transplantation, Others) and By End User (Hospitals, Dental Clinics, Oncology Hospitals, Research Institutes) - Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    US Oral Mucositis Market Research Report - Forecast to 2035 Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Table of Contents

    US Oral Mucositis Market Summary

    The United States Oral Mucositis market is projected to grow significantly from 140 USD Million in 2024 to 290 USD Million by 2035.

    Key Market Trends & Highlights

    US Oral Mucositis Key Trends and Highlights

    • The market is expected to experience a compound annual growth rate (CAGR) of 6.84 percent from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 290 USD Million, indicating robust growth opportunities.
    • In 2024, the market is valued at 140 USD Million, reflecting the current demand for oral mucositis treatments in the United States.
    • Growing adoption of innovative treatment options due to increasing prevalence of cancer therapies is a major market driver.

    Market Size & Forecast

    2024 Market Size 140 (USD Million)
    2035 Market Size 290 (USD Million)
    CAGR (2025-2035) 6.84%

    Major Players

    Teva Pharmaceutical Industries, Celgene, Novartis, AstraZeneca, Merck, Eli Lilly, GlaxoSmithKline, Bristol-Myers Squibb, Eisai, Pfizer, Amgen, Spectrum Pharmaceuticals, Mylan, Sankyo

    US Oral Mucositis Market Trends

    The US Oral Mucositis Market is experiencing significant trends driven by the increasing prevalence of cancer and the consequent rise in treatments such as chemotherapy and radiation therapy, which often lead to oral mucositis. The growing emphasis on supportive care has led to a higher demand for effective treatment options that alleviate symptoms associated with mucositis. Furthermore, technological advancements in drug formulations and the development of innovative products are enhancing treatment efficacy and patient comfort. These factors collectively represent key market drivers fueling growth in the sector.

    Opportunities to be explored in the US market lie in the increasing focus on preventive measures and the implementation of personalized treatment plans.There is a notable trend toward incorporating natural and organic products into treatment protocols. Additionally, rising awareness among healthcare providers regarding the impact of oral health on treatment outcomes creates avenues for the introduction of new products and services tailored to this specific patient demographic.

    In recent times, growing collaborations between pharmaceutical companies and healthcare organizations have been observed, aimed at improving treatment protocols and patient care practices. Additionally, clinical research is increasingly focusing on identifying biomarkers to predict the onset of oral mucositis, enabling earlier intervention strategies.The demand for comprehensive training programs for healthcare practitioners to manage oral mucositis better is also on the rise, signifying a shift toward more integrated care solutions. Overall, the evolving landscape of the US Oral Mucositis Market reflects a robust response to patient needs and highlights the importance of continuous innovation.

    US Oral Mucositis Market Drivers

    Market Segment Insights

    Oral Mucositis Market Cause Insights

    The US Oral Mucositis Market shows a complex landscape where various causes significantly contribute to the prevalence of oral mucositis, a common and painful side effect associated with cancer treatment. Among the primary causes, chemotherapy is widely recognized for its role in inducing oral mucositis due to the damage it inflicts on rapidly dividing cells in the oral mucosa. This segment is significant as it covers a wide variety of agents used in cancer therapies, leading to increased incidences of complications associated with oral health in patients.

    Moreover, radiotherapy is another key contributor, especially in head and neck cancer patients, where direct exposure significantly increases the risk of mucosal injury. The interaction of radiotherapy with the oral cavity's sensitive tissues showcases the need for targeted management strategies to alleviate symptoms. Additionally, hematopoietic stem cell transplantation plays a crucial role as a treatment modality for hematological malignancies, with patients undergoing this procedure often experiencing severe forms of oral mucositis due to the intensity of the conditioning therapies involved.

    Lastly, the “Others” category encompasses various non-cancer-related factors that can lead to oral mucositis, including infections and certain medications, further emphasizing the multi-faceted nature of this condition. With an aging population in the US, and a rising incidence of cancer, understanding these causes is crucial for healthcare professionals, enabling them to devise effective preventive and treatment strategies to minimize the impact of oral mucositis in affected patients.

    Overall, the understanding of the causes behind oral mucositis not only highlights the challenges within the US Oral Mucositis Market but also points to various opportunities for the development of innovative therapies and management options to improve patient outcomes in this domain.

    Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review

    Oral Mucositis Market End User Insights

    The End User segment of the US Oral Mucositis Market plays a critical role in addressing the needs of patients suffering from this condition, particularly within key facilities such as Hospitals, Dental Clinics, Oncology Hospitals, and Research Institutes. Hospitals stand at the forefront, equipped to provide intensive care and specialized treatments for severe cases of oral mucositis, driven by increasing patient admissions largely due to cancer therapies. Dental Clinics contribute significantly by focusing on preventative care and early diagnosis, thereby aiding in reducing disease severity.

    Oncology Hospitals are particularly crucial as they cater specifically to cancer patients, who are at high risk for developing oral mucositis due to their treatments, thereby presenting a major demand for effective management solutions. Research Institutes play a vital role in advancing the understanding of oral mucositis, spearheading studies into new treatment modalities and innovations that can change the landscape of patient care. Collectively, these End Users reflect a diverse landscape in the US Oral Mucositis Market, where the demand for improved therapeutic options continues to grow, amidst the ongoing challenges of patient adherence and treatment efficacy.

    Get more detailed insights about US Oral Mucositis Market Research Report - Forecast to 2035

    Regional Insights

    Key Players and Competitive Insights

    The US Oral Mucositis Market has witnessed notable developments owing to increasing awareness about the condition among healthcare professionals and patients. This awareness has stimulated research and innovation, leading to the introduction of various treatment modalities ranging from pharmaceuticals to supportive care products. The competition within this market is characterized by a blend of established players and emerging biotech firms focusing on the treatment and management of oral mucositis, particularly in patients undergoing radiotherapy or chemotherapy.

    The driving forces include a growing demographic of cancer patients, advancements in drug formulation, and an expanding pipeline of therapeutic options aimed at alleviating the painful and debilitating symptoms associated with oral mucositis. Companies are actively pursuing collaborations, clinical trials, and strategic partnerships to enhance their market presence and deliver effective solutions.

    Teva Pharmaceutical Industries has established itself as a significant player in the US Oral Mucositis Market with a portfolio centered on addressing the needs of patients suffering from this condition. The company's strengths lie in its robust research and development capabilities, which have enabled it to create various formulations that focus on symptom relief and oral care. Teva's extensive distribution network and partnerships with healthcare providers have further amplified its market presence, ensuring that its products reach the patients who need them most.

    Additionally, Teva benefits from a long-standing reputation in the pharmaceutical industry, allowing it to leverage its brand recognition to foster customer trust and loyalty among healthcare practitioners who prescribe treatments for oral mucositis.

    Celgene, a subsidiary of Bristol-Myers Squibb, holds a strong foothold in the US Oral Mucositis Market by delivering specialized solutions aimed at managing this challenging condition. The company’s key products are designed to mitigate the debilitating effects of oral mucositis, especially for oncology patients undergoing various treatments. Celgene's strengths are evident in its innovative approaches and emphasis on patient-centered care, making it a preferred choice among healthcare providers. The company has expanded its market presence through strategic mergers and acquisitions, acquiring products that complement its existing portfolio and enhance its capabilities in the oncology space.

    By focusing on high-quality research and maintaining a strong pipeline of therapeutic options, Celgene continues to play a crucial role in addressing the unmet needs of patients suffering from oral mucositis in the US market.

    Key Companies in the US Oral Mucositis Market market include

    Industry Developments

    Recent developments in the US Oral Mucositis Market have showcased significant advancements in the treatment landscape. Notably, Teva Pharmaceutical Industries and Bristol-Myers Squibb are focusing on enhancing their therapeutic options, while Novartis has reported substantial growth in their Oral Mucositis treatment portfolio. In September 2023, AstraZeneca expanded its research initiatives to address unmet needs in this area. The market has witnessed intensified competition, with Eli Lilly and Merck actively engaging in clinical trials for new formulations.

    In terms of mergers and acquisitions, Celgene made headlines in August 2023 with its acquisition of a niche biotech firm specializing in Oral Mucositis therapies, a move that enhances its product pipeline. Additionally, GlaxoSmithKline has partnered with Spectrum Pharmaceuticals for collaborative research on treatment efficacy. The rising prevalence of Oral Mucositis in patients undergoing chemotherapy and radiation therapy has contributed to a surge in market valuation, as healthcare systems prioritize effective management strategies. Over the past couple of years, significant investments in Research and Development have been directed towards innovative treatment approaches, further shaping the market dynamics.

    Market Segmentation

    Oral Mucositis Market Cause Outlook

    • Chemotherapy
    • Radiotherapy
    • Hematopoietic Stem Cell Transplantation
    • Others

    Oral Mucositis Market End User Outlook

    • Hospitals
    • Dental Clinics
    • Oncology Hospitals
    • Research Institutes

    Report Scope

    Report Attribute/Metric Source: Details
    MARKET SIZE 2018 120.58(USD Million)
    MARKET SIZE 2024 140.0(USD Million)
    MARKET SIZE 2035 290.0(USD Million)
    COMPOUND ANNUAL GROWTH RATE (CAGR) 6.844% (2025 - 2035)
    REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR 2024
    MARKET FORECAST PERIOD 2025 - 2035
    HISTORICAL DATA 2019 - 2024
    MARKET FORECAST UNITS USD Million
    KEY COMPANIES PROFILED Teva Pharmaceutical Industries, Celgene, Novartis, AstraZeneca, Merck, Eli Lilly, GlaxoSmithKline, BristolMyers Squibb, Eisai, Pfizer, Amgen, Spectrum Pharmaceuticals, Mylan, Sankyo
    SEGMENTS COVERED Cause, End User
    KEY MARKET OPPORTUNITIES Increased prevalence of cancer patients, Growing demand for innovative treatments, Expansion of telehealth solutions, Rising awareness of oral health, Development of targeted therapies
    KEY MARKET DYNAMICS rising cancer prevalence, increasing geriatric population, growing awareness and diagnosis, advancements in treatment options, rising demand for supportive care products
    COUNTRIES COVERED US

    Market Highlights

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Leave a Comment

    FAQs

    What is the expected market size of the US Oral Mucositis Market in 2024?

    The US Oral Mucositis Market is expected to be valued at 140.0 USD Million in 2024.

    What will be the market valuation of the US Oral Mucositis Market by 2035?

    By 2035, the US Oral Mucositis Market is anticipated to reach a valuation of 290.0 USD Million.

    What is the expected CAGR for the US Oral Mucositis Market from 2025 to 2035?

    The expected CAGR for the US Oral Mucositis Market from 2025 to 2035 is 6.844%.

    Which segment of the US Oral Mucositis Market is projected to have the highest valuation in 2035?

    The chemotherapy segment is projected to reach a valuation of 100.0 USD Million in 2035.

    What will be the market size of the radiotherapy segment in 2035?

    The radiotherapy segment of the US Oral Mucositis Market is expected to be valued at 65.0 USD Million in 2035.

    Who are the major players in the US Oral Mucositis Market?

    Key players in the US Oral Mucositis Market include Teva Pharmaceutical Industries, Celgene, Novartis, AstraZeneca, and Merck.

    What is the expected market size for hematopoietic stem cell transplantation by 2035?

    The hematopoietic stem cell transplantation segment is expected to reach a market size of 55.0 USD Million by 2035.

    How much is the 'Others' category expected to grow by 2035 in the US Oral Mucositis Market?

    The 'Others' category in the US Oral Mucositis Market is projected to grow to 70.0 USD Million by 2035.

    What are the key growth drivers for the US Oral Mucositis Market?

    Key growth drivers include increasing incidences of cancer therapies that cause oral mucositis and rising awareness about treatment options.

    What challenges are currently facing the US Oral Mucositis Market?

    Challenges in the market include stringent regulatory requirements and the high cost associated with some treatment options.

    1. EXECUTIVE SUMMARY
    2. Market Overview
    3. Key Findings
    4. Market Segmentation
    5. Competitive Landscape
    6. Challenges and Opportunities
    7. Future Outlook
    8. MARKET INTRODUCTION
    9. Definition
    10. Scope of the study
    11. Research Objective
    12. Assumption
    13. Limitations
    14. RESEARCH METHODOLOGY
    15. Overview
    16. Data Mining
    17. Secondary Research
    18. Primary Research
    19. Primary Interviews and Information Gathering Process
    20. Breakdown of Primary Respondents
    21. Forecasting Model
    22. Market Size Estimation
    23. Bottom-Up Approach
    24. Top-Down Approach
    25. Data Triangulation
    26. Validation
    27. MARKET DYNAMICS
    28. Overview
    29. Drivers
    30. Restraints
    31. Opportunities
    32. MARKET FACTOR ANALYSIS
    33. Value chain Analysis
    34. Porter's Five Forces Analysis
    35. Bargaining Power of Suppliers
    36. Bargaining Power of Buyers
    37. Threat of New Entrants
    38. Threat of Substitutes
    39. Intensity of Rivalry
    40. COVID-19 Impact Analysis
    41. Market Impact Analysis
    42. Regional Impact
    43. Opportunity and Threat Analysis
    44. US Oral Mucositis Market, BY Cause (USD Million)
    45. Chemotherapy
    46. Radiotherapy
    47. Hematopoietic Stem Cell Transplantation
    48. Others
    49. US Oral Mucositis Market, BY End User (USD Million)
    50. Hospitals
    51. Dental Clinics
    52. Oncology Hospitals
    53. Research Institutes
    54. Competitive Landscape
    55. Overview
    56. Competitive Analysis
    57. Market share Analysis
    58. Major Growth Strategy in the Oral Mucositis Market
    59. Competitive Benchmarking
    60. Leading Players in Terms of Number of Developments in the Oral Mucositis Market
    61. Key developments and growth strategies
    62. New Product Launch/Service Deployment
    63. Merger & Acquisitions
    64. Joint Ventures
    65. Major Players Financial Matrix
    66. Sales and Operating Income
    67. Major Players R&D Expenditure. 2023
    68. Company Profiles
    69. Teva Pharmaceutical Industries
    70. Financial Overview
    71. Products Offered
    72. Key Developments
    73. SWOT Analysis
    74. Key Strategies
    75. Celgene
    76. Financial Overview
    77. Products Offered
    78. Key Developments
    79. SWOT Analysis
    80. Key Strategies
    81. Novartis
    82. Financial Overview
    83. Products Offered
    84. Key Developments
    85. SWOT Analysis
    86. Key Strategies
    87. AstraZeneca
    88. Financial Overview
    89. Products Offered
    90. Key Developments
    91. SWOT Analysis
    92. Key Strategies
    93. Merck
    94. Financial Overview
    95. Products Offered
    96. Key Developments
    97. SWOT Analysis
    98. Key Strategies
    99. Eli Lilly
    100. Financial Overview
    101. Products Offered
    102. Key Developments
    103. SWOT Analysis
    104. Key Strategies
    105. GlaxoSmithKline
    106. Financial Overview
    107. Products Offered
    108. Key Developments
    109. SWOT Analysis
    110. Key Strategies
    111. BristolMyers Squibb
    112. Financial Overview
    113. Products Offered
    114. Key Developments
    115. SWOT Analysis
    116. Key Strategies
    117. Eisai
    118. Financial Overview
    119. Products Offered
    120. Key Developments
    121. SWOT Analysis
    122. Key Strategies
    123. Pfizer
    124. Financial Overview
    125. Products Offered
    126. Key Developments
    127. SWOT Analysis
    128. Key Strategies
    129. Amgen
    130. Financial Overview
    131. Products Offered
    132. Key Developments
    133. SWOT Analysis
    134. Key Strategies
    135. Spectrum Pharmaceuticals
    136. Financial Overview
    137. Products Offered
    138. Key Developments
    139. SWOT Analysis
    140. Key Strategies
    141. Mylan
    142. Financial Overview
    143. Products Offered
    144. Key Developments
    145. SWOT Analysis
    146. Key Strategies
    147. Sankyo
    148. Financial Overview
    149. Products Offered
    150. Key Developments
    151. SWOT Analysis
    152. Key Strategies
    153. References
    154. Related Reports
    155. US Oral Mucositis Market SIZE ESTIMATES & FORECAST, BY CAUSE, 2019-2035 (USD Billions)
    156. US Oral Mucositis Market SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD Billions)
    157. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    158. ACQUISITION/PARTNERSHIP
    159. MARKET SYNOPSIS
    160. US ORAL MUCOSITIS MARKET ANALYSIS BY CAUSE
    161. US ORAL MUCOSITIS MARKET ANALYSIS BY END USER
    162. KEY BUYING CRITERIA OF ORAL MUCOSITIS MARKET
    163. RESEARCH PROCESS OF MRFR
    164. DRO ANALYSIS OF ORAL MUCOSITIS MARKET
    165. DRIVERS IMPACT ANALYSIS: ORAL MUCOSITIS MARKET
    166. RESTRAINTS IMPACT ANALYSIS: ORAL MUCOSITIS MARKET
    167. SUPPLY / VALUE CHAIN: ORAL MUCOSITIS MARKET
    168. ORAL MUCOSITIS MARKET, BY CAUSE, 2025 (% SHARE)
    169. ORAL MUCOSITIS MARKET, BY CAUSE, 2019 TO 2035 (USD Billions)
    170. ORAL MUCOSITIS MARKET, BY END USER, 2025 (% SHARE)
    171. ORAL MUCOSITIS MARKET, BY END USER, 2019 TO 2035 (USD Billions)
    172. BENCHMARKING OF MAJOR COMPETITORS

    US Oral Mucositis Market Segmentation

     

     

     

    • Oral Mucositis Market By Cause (USD Million, 2019-2035)

      • Chemotherapy
      • Radiotherapy
      • Hematopoietic Stem Cell Transplantation
      • Others

     

    • Oral Mucositis Market By End User (USD Million, 2019-2035)

      • Hospitals
      • Dental Clinics
      • Oncology Hospitals
      • Research Institutes

     

     

     

     

     

     

    Report Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials